

Bulletin from the extraordinary general meeting in PMD Device Solutions AB (publ)

Extraordinary general meeting of PMD Device Solutions AB (publ), reg. no 556639–6809 (the "Company"), was held today, 29 October 2024 at 11.00 CET in Stockholm. The meeting resolved, with required majority, on all proposed matters in accordance with the board's previously announced proposals. The following is a summary of the main decisions taken.

Resolution on number of directors

The meeting resolved that the board of directors shall consist of three (3) directors, without deputies, for the time until the next annual general meeting.

Election of the board of directors

The meeting resolved that the board of directors shall consist of Martin Roos (new election), Sten Dahlborg (new election) and Myles Murray. It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman.

Martin Roos

Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech.

He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries.

Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago.

Martin is married with two kids, and he holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm.

Sten Dahlborg

Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management.

He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector.

Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.

For additional information, please contact

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com

The Company's Certified Adviser is Redeye.

Information about PMDS

PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital acute monitoring sector and the remote monitoring homecare sector. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company's shares are listed on Nasdaq First North Growth Market (STO: PMDS).

Attachments

[Bulletin from the extraordinary general meeting in PMD Device Solutions AB \(publ\)](#)